AKCEA THERAPEUTICS, INC. Contracts & Agreements

Agreement and Plan of Merger, dated as of August 30, 2020, among the Company, Ionis Pharmaceuticals, Inc. and Avalanche Merger Sub, Inc. (Schedules to the Agreement and Plan of... (Filed With SEC on August 31, 2020)

Offer Letter between William Andrews and the Company dated June 18, 2020 (Filed With SEC on July 9, 2020)

Severance Benefit Agreement between William Andrews and the Company dated July 9, 2020 (Filed With SEC on July 9, 2020)

Separation Agreement between Louis St. L. ODea and the Company dated July 7, 2020 (Filed With SEC on July 9, 2020)

Consulting Agreement between Louis St. L. ODea and the Company dated July 7, 2020 (Filed With SEC on July 9, 2020)

Michael D. Price Offer Letter (Filed With SEC on May 18, 2020)

Michael D. Price Severance Benefit Agreement (Filed With SEC on May 18, 2020)

Non-Employee Director Compensation Plan (Filed With SEC on May 6, 2020)

Strategic Advisory Services Agreement, by and between Registrant and B. Lynne Parshall dated, January 9, 2020 (Filed With SEC on May 6, 2020)

Severance Benefit Agreement between the Company and Robert Dolski dated May 23, 2019 (Filed With SEC on April 29, 2020)

Separation Agreement between the Company and Michael MacLean entered into on April 4, 2020 (Filed With SEC on April 9, 2020)

Retention Agreement between Louis St. L. ODea and the Company dated March 16, 2020 (Filed With SEC on March 20, 2020)

Severance Benefit Agreement between Louis St. L. ODea and the Company dated March 16, 2020 (Filed With SEC on March 20, 2020)

Global Option Agreement between Louis St. L. ODea and the Company dated March 16, 2020 (Filed With SEC on March 20, 2020)

Offer Letter (Filed With SEC on March 11, 2020)

Severance Benefit Agreement (Filed With SEC on March 11, 2020)

Akcea Therapeutics, Inc. 2015 Equity Incentive Plan, as amended (Filed With SEC on March 4, 2020)

Description Of Securities Registered Pursuant To Section 12 Of The Securities Exchange Act Of 1934, As Amended (Filed With SEC on March 2, 2020)

Non-Employee Director Compensation Plan (Filed With SEC on March 2, 2020)

License Agreement by and among Registrant and Pfizer Inc. dated October 4, 2019 (Filed With SEC on March 2, 2020)

Alex Howarth Offer Letter (Filed With SEC on December 4, 2019)

Alex Howarth Severance Benefit Agreement (Filed With SEC on December 4, 2019)

Consulting Agreement, by and between Akcea Therapeutics, Inc. and Jeffrey M. Goldberg, dated September 18, 2019 (Filed With SEC on November 6, 2019)

Separation Agreement, by and between Akcea Therapeutics, Inc. and Paula Soteropoulos, dated September 18, 2019 (Filed With SEC on November 6, 2019)

Separation Agreement, by and between Akcea Therapeutics, Inc. and Sarah Boyce, dated September 18, 2019 (Filed With SEC on November 6, 2019)

Separation Agreement, by and between Akcea Therapeutics, Inc. and Jeffrey M. Goldberg, dated September 18, 2019 (Filed With SEC on November 6, 2019)

Consulting Agreement, by and between Akcea Therapeutics, Inc. and Paula Soteropoulos, dated September 18, 2019 (Filed With SEC on November 6, 2019)

Amendment to Consulting Agreement, by and between Akcea Therapeutics, Inc. and Paula Soteropoulos, dated October 30, 2019 (Filed With SEC on November 6, 2019)

Kyle Jenne Offer Letter (Filed With SEC on October 23, 2019)

Kyle Jenne Severance Benefit Agreement (Filed With SEC on October 23, 2019)

Letter Agreement between Mike MacLean and the Company dated October 11, 2019 (Filed With SEC on October 17, 2019)

Akcea Damien McDevitt Offer Letter (Filed With SEC on September 23, 2019)

Akcea - Severance Agreement_McDevitt Damien (Filed With SEC on September 23, 2019)

Amendment No. 1 to the Strategic Collaboration, Option and License Agreement between the Registrant and Novartis Pharma AG dated February 22, 2019 (Filed With SEC on May 9, 2019)

Operating Sublease Agreement by and among Registrant and Ionis Pharmaceuticals, Inc., dated November 12, 2018 (Filed With SEC on March 1, 2019)

Non-Employee Director Compensation Plan (Filed With SEC on March 1, 2019)

Akcea Therapeutics, Inc. 2015 Equity Incentive Plan, as amended (Filed With SEC on November 23, 2018)

Collaboration and License Agreement dated August 1, 2018 by and between Akcea Therapeutics, Inc. and PTC Therapeutics International Limited (Filed With SEC on November 6, 2018)

Lease dated April 5, 2018 by and between Akcea Therapeutics, Inc. and MEPT Seaport 13 Stillings LLC (Filed With SEC on August 7, 2018)

Offer Letter dated April 17, 2018 by and between Akcea Therapeutics, Inc. and Sarah Boyce (Filed With SEC on August 7, 2018)

Second Amendment of Lease dated May 18, 2018 by and between Akcea Therapeutics, Inc. and 55 Cambridge Parkway, LLC (Filed With SEC on August 7, 2018)

Akcea Therapeutics, Inc. 2015 Equity Incentive Plan, as amended (Filed With SEC on May 7, 2018)

Akcea Therapeutics, Inc. 2015 Equity Incentive Plan, as amended (Filed With SEC on April 20, 2018)

Offer Letter, dated April 17, 2018, between the Company and Sarah Boyce (Filed With SEC on April 17, 2018)

Amended and Restated Investor Rights Agreement, dated March 14, 2018, by and between Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc (Filed With SEC on March 15, 2018)

Development, Commercialization, Collaboration and License Agreement, dated March 14, 2018, by and between Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc (Filed With SEC on March 15, 2018)

Stock Purchase Agreement, dated March 14, 2018, by and between Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc (Filed With SEC on March 15, 2018)

Amended and Restated Services Agreement, dated March 14, 2018, by and between Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc (Filed With SEC on March 15, 2018)

Stockholder Voting Agreement, dated March 14, 2018, by and between Akcea Therapeutics, Inc. and Novartis Pharma AG (Filed With SEC on March 15, 2018)

Form of Severance Benefit Agreement (Filed With SEC on November 30, 2017)

Offer Letter, dated as of July 17, 2017, by and between Akcea Therapeutics, Inc. and Mike MacLean (Filed With SEC on September 5, 2017)

AKCEA THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: DECEMBER 16, 2015 APPROVED BY THE STOCKHOLDERS: DECEMBER 16, 2015 AMENDED BY THE BOARD OF... (Filed With SEC on June 20, 2017)

AKCEA THERAPEUTICS, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 2, 2017 APPROVED BY THE STOCKHOLDERS: JUNE 19, 2017 IPO DATE/EFFECTIVE DATE: ,... (Filed With SEC on June 20, 2017)

INDEMNITY AGREEMENT (Filed With SEC on April 10, 2017)

STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN AKCEA THERAPEUTICS, INC. AND NOVARTIS PHARMA AG (Filed With SEC on April 10, 2017)

AKCEA THERAPEUTICS, INC. Shares of Common Stock Underwriting Agreement (Filed With SEC on March 27, 2017)

AKCEA THERAPEUTICS, INC. INVESTOR RIGHTS AGREEMENT DECEMBER 18, 2015 (Filed With SEC on March 27, 2017)

AKCEA THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: DECEMBER 16, 2015 APPROVED BY THE STOCKHOLDERS: DECEMBER 16, 2015 TERMINATION DATE: DECEMBER... (Filed With SEC on March 27, 2017)

DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT between ISIS PHARMACEUTICALS, INC. and AKCEA THERAPEUTICS, INC. (Filed With SEC on March 27, 2017)

SERVICES AGREEMENT (Filed With SEC on March 27, 2017)

SENIOR UNSECURED LINE OF CREDIT AGREEMENT (Filed With SEC on March 27, 2017)

STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN AKCEA THERAPEUTICS, INC. AND NOVARTIS PHARMA AG (Filed With SEC on March 27, 2017)

STOCK PURCHASE AGREEMENT (Filed With SEC on March 27, 2017)

OFFICE LEASE AGREEMENT 55 CAMBRIDGE PARKWAY CAMBRIDGE, MA by and between 55 CAMBRIDGE PARKWAY, LLC, a Delaware limited liability company, as Landlord and AKCEA THERAPEUTICS, INC.... (Filed With SEC on March 27, 2017)

AMENDMENT OF LEASE (Filed With SEC on March 27, 2017)

SECOND AMENDMENT OF LEASE (Filed With SEC on March 27, 2017)

Category

Industry

Companies

Contracts

AKCEA THERAPEUTICS, INC. Contracts & Agreements